bispecif
monoclon
antibodi
bsmab
uniqu
engin
heterobifunct
macromolecul
two
distinct
bind
specif
within
singl
molecul
cao
suresh
suresh
et
al
repres
second
gener
monoclon
antibodi
although
structur
bival
function
unival
bind
molecul
typic
bsmab
one
paratop
specif
particular
protein
antigen
anoth
paratop
specif
detect
moieti
enzym
fig
bsmab
therefor
function
versatil
heterobifunct
crosslink
bind
bsmab
molecul
depend
affin
interact
highli
specif
bsmab
produc
three
method
chemic
conjug
involv
chemic
crosslink
origin
method
bsmab
product
b
somat
hybrid
involv
hybridoma
technolog
c
genet
engin
involv
recombin
dna
technolog
da
suresh
product
bsmab
hybridoma
technolog
involv
bifunct
fusion
fig
two
differ
hybridoma
produc
distinct
monoclon
antibodi
common
compar
bsmab
product
method
kohler
milstein
bsmab
exploit
varieti
vivo
vitro
applic
rang
diagnost
therapeut
cao
suresh
use
bsmab
differ
therapeut
applic
gene
therapi
describ
detail
earlier
chapter
chapter
focus
diagnost
applic
bsmab
bsmab
function
excel
diagnost
immunoprob
due
intrins
bind
site
two
molecul
predetermin
order
offer
distinct
advantag
convent
probe
use
diagnost
assay
due
monoval
one
antigen
simultan
bind
marker
enzym
one
epitop
bsmab
usual
direct
marker
enzym
hors
radish
peroxidas
hrpo
alkalin
phosphatas
enabl
signal
gener
immunodiagnost
assay
bsmab
use
number
diagnost
applic
immunoassay
immunohistochemistri
radioimmunodiagnosi
kreutz
suresh
suresh
suresh
et
al
use
diagnost
assay
revolution
field
immunodiagnost
due
higher
sensit
reproduc
achiev
assay
main
advantag
use
bsmab
immunodiagnost
maximum
specif
activ
function
effici
achiev
sinc
everi
antibodi
molecul
associ
signal
gener
molecul
kreutz
suresh
addit
make
diagnost
assay
rapid
bsmab
enhanc
sensit
specif
detect
significantli
reduc
even
elimin
fals
posit
reaction
especi
assay
elisa
case
immunohistochemistri
use
bsmab
lead
decreas
background
fine
sharp
morpholog
inform
clear
distinct
identif
immun
reactiv
side
good
resolut
ultrastructur
detail
milstein
cuello
suresh
et
al
advantag
use
bsmab
immunodiagnost
assay
includ
improv
signal
nois
ratio
simplif
assay
procedur
easili
use
nanoprob
make
ultrasensit
detect
possibl
especi
case
competit
immunoassay
contrast
bsmab
chemic
conjug
monoclon
polyclon
antibodi
often
exhibit
higher
background
liu
et
al
tradit
monoclon
antibodi
employ
mani
immunodiagnost
assay
typic
use
monoclon
antibodi
diagnost
applic
requir
chemic
manipul
antibodi
chemic
crosslink
order
conjug
detect
moieti
enzym
biotin
onto
antibodi
chemic
crosslink
detect
moieti
antibodi
mani
disadvantag
outlin
kricka
milstein
cuello
random
process
combin
ratio
antibodi
conjug
chemic
fix
gener
result
batch
batch
variat
detect
reagent
produc
b
size
result
conjug
antibodi
uniform
influenc
abil
penetr
especi
critic
immunohistochem
applic
c
inactiv
activ
site
bind
site
detect
moieti
antibodi
andor
aggreg
may
occur
chemic
conjug
coval
linkag
occur
detect
moieti
antibodi
prefer
vivo
diagnost
applic
e
antibodi
produc
often
low
specif
activ
decreas
shelf
life
factor
signific
impact
perform
conjug
monoclon
antibodi
therefor
reproduc
immunodiagnost
assay
method
contrast
use
bsmab
complet
elimin
need
chemic
conjug
antibodi
detect
moieti
bispecif
natur
bsmab
ensur
combin
ratio
antibodi
detect
moieti
alway
sinc
bsmab
gener
alreadi
tag
detect
enzym
purif
step
extra
step
enzym
addit
subsequ
wash
avoid
immunoassay
bsmab
function
uniform
homogen
immunoconjug
reproduc
high
specif
activ
therefor
serv
excel
altern
chemic
conjug
monoclon
antibodi
bsmab
extrem
versatil
function
robust
immunoconjug
assay
use
varieti
immunodiagnost
assay
design
multipl
format
includ
convent
format
microtitr
plate
assay
well
newer
format
swab
strip
filter
disk
assay
newer
format
end
point
assay
read
visual
without
need
instrument
make
immunoassay
extrem
conveni
use
point
care
detect
test
divers
health
care
set
accord
world
health
organ
million
death
due
tuberculosi
tb
alon
year
whotb
world
health
organ
report
tb
lack
earli
detect
infect
individu
result
rapid
spread
diseas
differ
part
world
problem
compound
due
coinfect
human
immunodefici
viru
hiv
led
steep
increas
morbid
mortal
fact
tb
becom
lead
caus
death
hivinfect
patient
whotb
world
health
organis
report
tb
tb
caus
bacterium
mycobacterium
tuberculosi
highli
resili
rampant
worldwid
current
diagnosi
tuberculosi
mainli
reli
result
sputum
smear
microscopi
ssm
bacteri
cultur
method
use
earli
stage
detect
ssm
sensit
detect
bacteri
load
sputum
moreov
often
difficult
collect
sputum
sampl
elderli
pediatr
popul
especi
vulner
tuberculosi
infect
due
weak
immun
system
bacteri
cultur
method
still
regard
gold
standard
detect
tuberculosi
take
day
provid
result
also
requir
dedic
cultur
facil
major
tb
case
due
problem
detect
often
perform
base
clinic
symptom
result
chest
radiogram
howev
none
method
specif
mani
pulmonari
diseas
also
show
similar
symptom
chest
radiogram
result
delay
faulti
diagnosi
system
patient
often
treat
incorrectli
case
partli
contribut
bacteri
evolut
toward
multidrug
resist
mdr
extrem
drug
resist
xdr
strain
tuberculosi
recent
sophist
molecular
assay
interferon
gamma
releas
assay
igra
nucleic
acid
amplif
naa
assay
becom
avail
howev
perform
also
question
campo
et
al
lalvani
millington
madariaga
et
al
molecular
assay
moreov
difficult
perform
resourceconstrain
countri
due
high
cost
requir
technic
sophist
current
simpl
rapid
inexpens
point
care
immunodiagnost
assay
avail
detect
tuberculosi
laboratori
therefor
develop
novel
highli
sensit
immunodiagnost
assay
detect
tuberculosi
use
bsmab
sarkar
suresh
univers
alberta
unpublish
data
gener
outlin
develop
bsmabbas
immunodiagnost
assay
describ
design
immunoassay
either
strip
swab
format
specif
tuberculosi
antigen
use
gener
bsmab
unravel
complet
genom
sequenc
tuberculosi
cole
et
al
made
easier
identifi
antigen
highli
specif
bacteria
relat
member
mycobacteria
import
tuberculosi
antigen
palmanicola
bocanegragarcia
could
possibl
candid
bsmab
gener
mention
tabl
chosen
tuberculosi
antigen
use
first
gener
monoclon
antibodi
subsequ
step
hybridoma
secret
monoclon
antibodi
fuse
anoth
hybridoma
secret
monoclon
antibodi
detect
enzym
like
hrpo
alkalin
phosphatas
obtain
hybridhybridoma
quadroma
produc
desir
bsmab
kreutz
et
al
suresh
et
al
isol
stabl
clone
express
bsmab
expand
bioreactor
subsequ
bsmab
purifi
use
affin
chromatographi
laboratori
design
novel
purif
process
isol
bsmab
one
fusion
monoclon
antibodi
partner
direct
hrpo
bhatnagar
et
al
process
allow
high
effici
purif
bsmab
use
maminophenylboron
acid
agaros
column
along
hrpo
tag
gener
format
immunoassay
involv
coat
solid
phase
swab
strip
tuberculosi
antigenspecif
monoclon
antibodi
block
unbound
site
use
suitabl
buffer
coat
block
swabstrip
incub
clinic
specimen
collect
patient
tuberculosi
antigen
present
sampl
would
specif
bind
monoclon
antibodi
nonspecif
unbound
materi
wash
purifi
bsmab
use
detect
antibodi
one
arm
bsmab
recogn
antigen
would
bind
antigen
form
sandwich
given
bsmab
alreadi
tag
hrpo
addit
enzym
substrat
tmb
result
format
blue
color
easili
identifi
schemat
gener
assay
format
shown
fig
bsmabbas
immunodiagnost
assay
detect
tuberculosi
infect
sever
distinct
advantag
assay
highli
specif
sensit
time
easi
perform
sinc
requir
technic
expertis
addit
result
assay
obtain
within
hour
sampl
collect
also
end
point
read
visual
furthermor
design
assay
make
inexpens
test
easili
perform
resourceconstrain
set
e
coli
belong
group
verocytotoxin
shiga
toxin
produc
e
coli
surfac
import
food
waterborn
pathogen
worldwid
fraser
et
al
law
caus
nonbloodi
bloodi
diarrhea
hemorrhag
coliti
hemolyt
urem
syndrom
character
hemolyt
anemia
thrombocytopenia
acut
renal
failur
griffin
taux
e
coli
therefor
classifi
enterohemorrhag
e
coli
ehec
report
caus
case
infect
per
year
unit
state
alon
mead
et
al
sever
outbreak
e
coli
infect
associ
recreat
municip
drink
water
north
america
unit
kingdom
japan
bopp
et
al
hrudey
et
al
current
method
detect
e
coli
water
food
tradit
enrich
plate
sorbitol
macconkey
agar
rainbow
agar
select
media
polymeras
chain
reaction
pcr
immunolog
method
bennett
et
al
manafi
kremsmaier
main
drawback
method
includ
time
requir
h
cultur
difficulti
isol
dna
sampl
pcr
low
sensit
import
note
low
coloni
form
unit
cfu
e
coli
present
contamin
food
water
gener
suffici
caus
sever
infect
therefor
sensit
method
detect
investig
outbreak
vital
highli
sensit
bsmabbas
immunodetect
assay
develop
laboratori
detect
e
coli
water
sampl
guttikonda
et
al
e
coli
whole
bacteria
e
coli
lipopolysaccharid
lp
use
first
gener
monoclon
antibodi
hybridoma
fuse
antihrpo
secret
monoclon
antibodi
hybridoma
kreutz
et
al
suresh
et
al
gener
quadroma
produc
bsmab
specif
e
coli
hrpo
bsmab
subsequ
purifi
use
benzhydroxamicacid
agaros
column
husereau
suresh
use
sandwich
elisa
immunoassay
anti
coli
monoclon
antibodi
use
captur
antibodi
bind
bacteria
sampl
bsmab
use
detect
antibodi
guttikonda
et
al
refer
fig
gener
assay
format
detect
limit
assay
found
cfuml
sampl
tap
water
lake
water
respect
immunoassay
adapt
immunofilt
assay
format
suit
public
health
applic
water
test
laboratori
guttikonda
et
al
low
cfu
e
coli
ml
water
detect
indic
assay
highli
sensit
moreov
assay
highli
specif
sinc
detect
excess
bacteri
strain
salmonella
pseudomona
well
nonpathogen
e
coli
higher
signal
nois
ratio
clean
background
achiev
assay
sinc
bsmab
serv
high
specif
activ
probe
bsmabbas
immunodetect
assay
therefor
function
robust
ultrasensit
quick
method
detect
e
coli
distinct
advantag
elimin
amplif
step
requir
current
assay
could
easili
develop
routin
screen
assay
detect
e
coli
water
bodi
especi
develop
countri
whoop
cough
pertussi
caus
bacterium
bordetella
pertussi
becom
major
health
concern
recent
year
especi
among
adolesc
age
group
cdcp
center
diseas
control
prevent
earli
accur
diagnosi
critic
order
prevent
spread
infect
also
ensur
proper
treatment
affect
individu
convent
diagnosi
b
pertussi
infect
involv
identif
bacterium
cultur
clinic
nasopharyng
aspir
sampl
gener
take
day
joseph
moreov
success
isol
character
turn
depend
sever
factor
proper
specimen
collect
respiratori
tract
storag
cultur
condit
gustafsson
et
al
anoth
method
detect
b
pertussi
involv
use
direct
fluorescentantibodi
assay
employ
fluorescencelabel
monoclon
antibodi
direct
predomin
antigen
lp
molecul
present
outer
membran
bacterium
mcnicol
et
al
peppler
although
detect
lp
good
strategi
assay
sensit
also
easi
perform
tilley
et
al
laboratori
therefor
develop
highli
sensit
simpl
bsmabbas
immunodiagnost
assay
detect
whole
b
pertussi
solubl
b
pertussi
lp
tang
et
al
assay
use
analyz
clinic
sampl
also
immunochem
structur
studi
serolog
character
b
pertussi
lp
antib
pertussi
lp
monoclon
antibodi
secret
hybridoma
antihrpo
monoclon
antibodi
secret
hybridoma
fuse
gener
quadroma
produc
bsmab
specif
b
pertussi
lp
hrpo
bsmab
subsequ
purifi
affin
chromatographi
use
benzhydroxamicacid
agaros
column
husereau
suresh
use
homosandwich
elisa
immunoassay
heatkil
b
pertussi
spike
nasopharyng
aspir
first
bound
antilp
specif
monoclon
antibodi
bsmab
ad
detect
antibodi
tang
et
al
refer
fig
gener
assay
format
assay
show
high
sensit
practic
lower
limit
detect
cfu
extrapol
theoret
lower
limit
detect
found
one
bacterium
use
mean
standard
deviat
control
assay
without
b
pertussi
interestingli
bind
b
pertussi
antib
pertussi
lp
monoclon
antibodyco
solid
phase
found
irrevers
despit
extens
wash
suggest
uniqu
molecular
velcro
effect
tang
et
al
use
bsmab
immunoassay
allow
ultrasensit
detect
b
pertussi
sinc
avidli
captur
multipl
expos
lp
molecul
bacteri
surfac
bsmabbas
immunodiagnost
assay
adapt
immunoswab
format
facilit
easi
rapid
point
care
detect
b
pertussi
primari
health
care
set
sensit
detect
high
sinc
ten
bacteria
could
detect
compar
control
tang
et
al
bsmabbas
assay
uniqu
advantag
highli
sensit
easi
perform
therefor
facilit
earli
detect
b
pertussi
infect
accur
monitor
outbreak
whoop
cough
sever
acut
respiratori
syndrom
sar
epidem
affect
peopl
worldwid
spread
countri
across
contin
outbreak
drosten
et
al
peiri
et
al
poon
et
al
highli
contagi
infect
claim
live
short
period
time
fatal
rate
emerg
huge
global
threat
human
health
sar
coronaviru
sarscov
etiolog
agent
sar
believ
transmit
wild
anim
human
popul
guan
et
al
wang
et
al
accord
absenc
rapid
screen
test
delay
diagnosi
suspect
case
sar
result
spread
diseas
worldwid
current
method
confirm
sar
infect
includ
detect
viral
rna
revers
transcriptionpcr
jiang
et
al
poon
et
al
yam
et
al
detect
sarscov
antibodi
bodi
fluid
use
indirect
fluoresc
assay
chan
et
al
isol
sarscov
clinic
sampl
keyaert
et
al
yamashita
et
al
sinc
viral
cultur
time
consum
tediou
insensit
method
pcr
antibodi
detect
method
wide
use
howev
two
method
expens
labori
requir
technic
expertis
wu
et
al
simpl
rapid
inexpens
diagnost
test
specif
earli
detect
sarscov
therefor
extrem
import
limit
spread
infect
proper
risk
manag
case
futur
global
outbreak
especi
sinc
sar
high
rate
transmiss
mortal
laboratori
develop
highli
sensit
rapid
simpl
bsmabbas
immunoswab
assay
earli
detect
sarscov
kammila
et
al
assay
design
detect
abund
conserv
viral
antigen
nucleocapsid
protein
np
di
et
al
hiscox
et
al
lau
et
al
rota
et
al
suresh
et
al
presenc
differ
bodi
fluid
serum
urin
nasopharyng
aspir
throat
wash
sampl
saliva
suggest
current
infect
three
differ
monoclon
antibodi
recogn
differ
epitop
np
antigen
antihrpo
monoclon
antibodi
employ
gener
bsmab
use
hybridhybridoma
technolog
obtain
antisarscov
antihrpo
bsmab
purifi
novel
dual
sequenti
affin
chromatographi
method
prote
column
follow
maminophenyleboron
acid
agaros
column
develop
laboratori
bhatnagar
et
al
immunoswab
assay
easytous
swab
first
coat
antisarscov
monoclon
antibodi
captur
np
test
sampl
follow
detect
bsmab
kammila
et
al
refer
fig
gener
assay
format
assay
success
detect
sarscov
np
antigen
spike
differ
matric
salin
serum
pig
nasopharyng
aspir
high
sensit
pig
nasopharyng
aspir
use
surrog
human
sampl
test
abil
immunoswab
assay
detect
low
concentr
np
antigen
immunoswab
assay
show
np
detect
limit
pgml
pgswab
salin
pgml
pgswab
pig
nasopharyng
aspir
pgml
pgswab
rabbit
serum
sensit
np
detect
high
bsmabbas
assay
compar
parallel
mabbas
assay
pgml
vs
pgml
salin
pgml
vs
pgml
pig
nasopharyng
aspir
indic
bsmabbas
immunoassay
work
better
mabbas
counterpart
furthermor
determin
robust
assay
swab
precoat
captur
antibodi
test
storag
time
period
differ
condit
kammila
et
al
bsmabbas
immunoswab
show
good
sensit
np
detect
even
week
pgml
storag
pgml
rt
storag
indic
good
shelflif
immunoswab
immunoswab
format
potenti
advantag
particularli
clinic
rural
primari
healthcar
set
eas
use
earli
phase
detect
limit
spread
infect
also
extrem
use
sar
screen
port
mass
human
entri
airport
seaport
bu
train
border
station
interestingli
time
requir
perform
assay
approxim
min
make
rapid
test
sar
diagnosi
kammila
et
al
assay
easili
use
screen
numer
suspect
individu
within
short
period
time
futur
sar
outbreak
given
rel
eas
access
nasopharyng
aspir
invas
procedur
bsmabbas
immunoswab
detect
sarscov
np
antigen
therefor
serv
simpl
point
care
diagnost
test
compar
current
method
di
et
al
also
highli
sensit
inexpens
requir
minim
train
personnel
dengu
fever
caus
dengu
viru
preval
mosquitoborn
viral
infect
world
million
case
report
year
predominantli
tropic
subtrop
region
hemungkorn
et
al
dengu
viru
belong
flavivirida
famili
four
differ
serotyp
identifi
far
human
dengu
viral
infect
caus
spectrum
diseas
rang
asymptomat
infect
sever
hemorrhag
fever
ultim
result
death
hemungkorn
et
al
diagnosi
dengu
infect
base
clinic
symptom
deem
reliabl
therefor
detect
specif
viru
viral
antigen
genom
sequenc
andor
antibodi
absolut
essenti
confirm
infect
current
method
diagnos
dengu
infect
includ
viru
isol
serolog
molecular
techniqu
employ
monoclon
polyclon
antibodi
label
enzymat
fluorometr
marker
shu
huang
method
less
reliabl
moreov
identifi
viru
viral
genom
expens
requir
special
laboratori
import
diagnos
ongo
recent
infect
acut
earli
convalesc
stage
order
facilit
better
treatment
ensur
effect
etiolog
investig
diseas
control
halstead
current
sensit
simpl
inexpens
diagnost
assay
avail
detect
dengu
viru
infect
acut
earli
stage
laboratori
develop
novel
highli
sensit
immunodiagnost
assay
detect
dengu
viru
use
bsmab
ganguli
suresh
univers
alberta
unpublish
data
gener
outlin
develop
bsmabbas
immunodiagnost
assay
describ
design
immunoassay
specif
dengu
viru
antigen
use
gener
bsmab
could
employ
simpl
strip
swab
assay
format
select
dengu
viru
antigen
use
first
gener
monoclon
antibodi
subsequ
step
hybridoma
secret
monoclon
antibodi
fuse
anoth
hybridoma
secret
monoclon
antibodi
specif
hrpo
produc
quadroma
produc
desir
bsmab
bsmab
subsequ
purifi
affin
chromatographi
use
maminophenylboron
acid
agaros
column
bhatnagar
et
al
gener
format
immunodiagnost
assay
involv
coat
dengu
viru
antigenspecif
monoclon
antibodi
captur
antibodi
calcium
algin
tip
swab
aluminumor
plastic
shaft
per
previous
publish
protocol
tang
et
al
swab
block
later
incub
specif
antigen
spike
serum
purifi
bsmab
use
detect
antibodi
addit
hrpo
substrat
tmb
result
format
blue
color
identifi
visual
refer
fig
gener
assay
format
bsmabbas
immunodiagnost
assay
dengu
viru
detect
sever
advantag
assay
highli
specif
easi
perform
sinc
requir
technic
expertis
sophist
instrument
addit
design
assay
make
rapid
conveni
point
care
detect
tool
apt
use
primari
health
care
set
remot
villag
featur
make
assay
suitabl
earli
detect
dengu
infect
therebi
control
spread
commun
prostat
cancer
common
men
respons
death
cancer
except
lung
cancer
nci
nation
cancer
institut
statist
new
case
prostat
cancer
diagnos
unit
state
alon
expect
men
diagnos
prostat
cancer
lifetim
littl
million
men
unit
state
survivor
prostat
cancer
nci
nation
cancer
institut
statist
prostatespecif
antigen
psa
use
tumorassoci
marker
present
serum
wide
use
screen
monitor
progress
prostat
cancer
caplan
kratz
sever
differ
assay
current
avail
measur
psa
involv
use
label
monoclon
polyclon
antibodi
armbrust
cattini
et
al
khosravi
et
al
klee
et
al
leinonen
et
al
oesterl
et
al
vihko
et
al
yu
diamandi
assay
technic
complex
time
consum
lower
sensit
laboratori
therefor
develop
novel
highli
sensit
rapid
bsmabbas
immunoassay
measur
psa
kreutz
suresh
antipsa
monoclon
antibodi
secret
hybridoma
fuse
antihrpo
secret
hybridoma
use
hybridhybridoma
technolog
gener
quadroma
produc
antipsa
antihrpo
bsmab
bsmab
purifi
ammonium
sulfat
precipit
anion
exchang
affin
chromatographi
use
psa
immunoassay
antipsa
monoclon
antibodi
use
captur
antibodi
bsmab
use
detect
antibodi
measur
psa
level
test
sampl
singlestep
assay
fig
assay
high
analyt
sensit
even
short
substrat
incub
time
detect
limit
compar
commerci
avail
assay
requir
longer
incub
time
kreutz
suresh
tmb
enzym
substrat
sensit
mgl
achiev
substrat
incub
comparison
commerci
avail
hybritech
tandemeiar
psa
assay
detect
limit
mgl
substrat
incub
develop
assay
evalu
use
clinic
sampl
result
found
correl
obtain
autom
hybritech
enzym
psa
immunoassay
kreutz
suresh
overal
bsmabbas
immunoassay
psa
measur
rapid
kinet
excel
detect
limit
make
good
candid
use
develop
nextgener
autom
immunoassay
rapid
screen
health
clinic
molecular
imag
transform
field
cancer
diagnosi
superior
abil
identifi
local
cancer
base
distinct
molecular
function
characterist
cancer
tissu
base
imag
use
positron
emiss
tomographi
pet
comput
tomographi
ct
becom
popular
detect
assess
differ
type
tumor
variou
specif
monoclon
antibodi
direct
differ
cancer
antigen
also
employ
howev
sensit
techniqu
low
compar
theori
monoclon
antibodi
ideal
imag
candid
owe
higher
degre
specif
tumor
antigen
abil
discrimin
tumor
inflamm
howev
high
molecular
weight
radiolabel
monoclon
antibodi
limit
tumor
uptak
caus
insuffici
clearanc
surround
tissu
result
low
contrast
imag
size
also
interfer
abil
molecul
extravas
vascular
channel
extravascular
space
thu
lead
slow
accret
radiolabel
antibodi
tumor
typic
day
achiev
maximum
tumor
uptak
tumor
uptak
radiolabel
monoclon
antibodi
may
reach
inject
dose
per
gram
tumor
mous
xenograft
model
may
accret
inject
dose
per
gram
tumor
human
owe
larger
vascular
extravascular
volum
distribut
although
sever
antibodi
modif
made
along
chang
radionuclid
moieti
order
obtain
better
signal
nois
ratio
avoid
nonspecif
tissu
uptak
liver
kidney
bone
marrow
none
yield
expect
result
recent
time
bsmab
proven
use
cancer
diagnost
imag
especi
use
pretarget
strategi
cardillo
et
al
gold
et
al
goldenberg
et
al
rearden
et
al
sharkey
et
al
strategi
aim
deliv
high
tumor
accret
elimin
background
nois
due
untarget
radioact
blood
normal
tissu
reduc
unintend
toxic
reli
bsmab
abil
effect
tumor
local
subsequ
administ
radiolabel
effector
molecul
target
achiev
bsmab
bind
target
antigen
one
arm
radiometalchel
hapten
peptid
complex
effector
molecul
arm
anim
model
experi
reveal
equival
tumor
uptak
bsmab
compar
radiolabel
antibodi
maximum
accret
within
minut
rather
sever
hour
day
even
radionuclid
clear
rapidli
bodi
product
elimin
urin
within
hour
allow
tumorblood
tissu
ratio
often
within
h
radionuclid
administr
tissu
retent
radiolabel
effector
molecul
also
found
low
even
kidney
liver
often
show
elev
uptak
directli
radiolabel
antibodi
unless
radioiodin
use
use
bsmab
significantli
enhanc
imag
util
pretarget
procedur
compar
use
directli
radiolabel
antibodi
decoupl
effector
molecul
pretarget
agent
central
variat
theme
result
enhanc
imag
tumor
bsmab
use
simpl
twostep
pretarget
approach
without
need
clear
step
addit
agent
twostep
procedur
gener
involv
inject
pretarget
agent
bsmab
wait
day
two
unbound
fraction
drain
bodi
circul
excret
liver
kidney
bsmab
easili
clear
blood
within
day
follow
administr
radiolabel
effector
molecul
would
bind
specif
arm
pretarget
bsmab
tumor
site
patient
would
therefor
abl
receiv
bsmab
inject
oncologist
return
day
later
receiv
radiolabel
product
nuclear
medicin
facil
imag
accomplish
day
although
may
take
day
imag
achiev
use
pretarget
approach
experienc
investig
preclin
data
suggest
imag
would
superior
term
specif
sensit
signal
intens
minim
background
compar
obtain
use
radiolabel
monoclon
antibodi
mani
case
bsmabbas
pretarget
approach
outperform
result
gener
clinic
approv
radiolabel
monoclon
antibodi
especi
imag
small
tumor
colorect
colon
cancer
sharkey
et
al
addit
give
better
tumorblood
ratio
superior
tumor
uptak
enhanc
tumornon
tumor
ratio
pretarget
strategi
retain
tumorspecif
signal
intens
even
day
postinject
radioact
effector
molecul
thu
provid
increas
signal
strength
tumor
site
bsmab
current
exploit
imag
mani
ceaexpress
tumor
pancreat
cancer
nonhodgkin
lymphoma
peltier
et
al
schuhmach
et
al
b
bsmabbas
pretarget
techniqu
diagnost
imag
cancer
taken
nuclear
imag
whole
new
level
begin
complement
presentday
gold
standard
bsmab
engin
achiev
optim
molecular
weight
charg
better
tumor
uptak
rapid
blood
clearanc
higher
valenc
improv
affin
taa
enhanc
signal
intens
greater
flexibl
bind
varieti
haptenpeptid
carri
differ
radioisotop
improv
method
use
product
bsmab
dock
lock
molecular
engin
strategi
applic
further
pretarget
applic
tumor
imag
therapi
describ
chap
given
highli
specif
sensit
imag
possibl
bsmab
pretarget
experiment
clinic
set
evid
bsmabbas
cancer
diagnost
imag
promis
use
bsmab
immunodiagnost
assay
result
develop
next
gener
immunoassay
highli
sensit
rapid
simpl
costeffect
specif
assay
approach
theoret
limit
immunodetect
make
ultrasensit
importantli
assay
invalu
point
care
diagnost
tool
assay
immens
valu
especi
resourceconstrain
countri
combat
spread
diseas
rapid
detect
communic
diseas
huge
impact
current
global
health
scenario
infecti
diseas
make
quick
transit
epidem
pandem
like
recent
outbreak
swine
flu
current
diagnost
assay
measur
specif
antibodi
bacteri
viral
antigen
therefor
may
report
previou
infect
sinc
antibodi
circul
blood
month
postinfect
assay
rare
detect
infect
initi
stage
make
earli
intervent
almost
imposs
contrast
bsmabbas
diagnost
measur
specif
bacteri
viral
antigen
rather
antibodi
therefor
accur
reflect
activ
diseas
state
make
earlystag
detect
possibl
come
year
bsmab
prove
valuabl
use
diagnosi
differ
type
cancer
sinc
bsmabbas
cancer
diagnosi
mani
advantag
highli
sensit
use
earli
detect
cancer
also
conveni
monitor
progress
diseas
state
assess
respons
treatment
given
immens
potenti
bsmab
excel
immunoprob
effort
engin
newer
form
antibodi
significantli
improv
bind
specif
avid
bsmab
await
plethora
novel
applic
field
diagnost
